Pharmaceutical Positive results from a Phase III study in adult patients with newly-diagnosed partial-onset seizures, sponsored by Portugal’s largest drugmaker Bial, show that treatment with once daily Zebinix (eslicarbazepine acetate) monotherapy is as effective as twice daily controlled-release carbamazepine, a standard of care, and is well-tolerated. 18 April 2016